Home › Therapeutic areas › Infectious Disease
Infectious Disease (21 companies · 24 conditions)
Conditions
Hepatitis B 5 COVID-19 4 Influenza 3 HIV 2 Pneumococcal Pneumonia 2 RSV 2 BK Virus Infection 1 Rare Chagas Disease 1 Cholera 1 Chronic Hepatitis Delta 1 Rare Community-Acquired Pneumonia 1 Cytomegalovirus Infection 1 Group A Streptococcal Infection 1 Hepatitis C 1 Invasive Fungal Infection 1 Invasive Pneumococcal Disease 1 Leishmaniasis 1 Melioidosis 1 Mycobacterium abscessus Lung Disease 1 Rare Mycobacterium avium Complex Lung Disease 1 Rare Nontuberculous Mycobacterial Lung Disease 1 Rare Shigellosis 1 Surgical Site Infection 1 Vulvovaginal Candidiasis 1
Companies
| Ticker | Company | Therapeutic areas | In Infectious Disease | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ADMA | Adma Biologics | ImmunologyInfectious Disease Rare | 2 | Approved | $2.82B | 4 |
| ANTX | AN2 Therapeutics | HematologyInfectious Disease+1 Rare | 3 | Phase 2 | $151M | 6 |
| BCRX | Biocryst Pharmaceuticals | DermatologyImmunology+1 Rare | 1 | Approved | $1.98B | 4 |
| CAPR | Capricor Therapeutics | Infectious DiseaseNeurology Rare | 1 | NDA Submitted | $523M | 2 |
| ENTA | Enanta Pharmaceuticals | DermatologyImmunology+1 | 5 | Approved | $320M | 7 |
| ETON | Eton Pharmaceuticals | GI/HepatologyInfectious Disease+3 Rare | 1 | Approved | $1.63B | 17 |
| FBIO | Fortress Biotech | DermatologyHematology+3 Rare | 1 | Approved | $61.7M | 12 |
| IBRX | ImmunityBio | Infectious DiseaseOncology | 1 | Approved | $9.15B | 16 |
| IMCR | Immunocore | DermatologyInfectious Disease+2 | 2 | Approved | $1.60B | 15 |
| INSM | Insmed | CardiovascularImmunology+3 Rare | 3 | Approved | $25.1B | 15 |
| IVVD | Invivyd | Infectious Disease | 4 | Approved | $166M | 5 |
| IONS | Ionis Pharmaceuticals | CardiovascularHematology+5 Rare | 1 | Approved | $6.55B | 29 |
| OCGN | Ocugen | Infectious DiseaseOphthalmology Rare | 4 | Phase 3 | $314M | 12 |
| PYPD | PolyPid | Infectious DiseaseOncology | 1 | NDA Submitted | $125M | 3 |
| DTIL | Precision Biosciences | Infectious DiseaseMetabolic+1 Rare | 1 | Phase 1 | $296M | 5 |
| SCYX | Scynexis | Infectious DiseaseRenal Rare | 4 | Approved | $34.8M | 5 |
| TTRX | Turn Therapeutics | DermatologyInfectious Disease Rare | 1 | Phase 2 | $282M | 4 |
| VNDA | Vanda Pharmaceuticals | CardiovascularDermatology+6 Rare | 1 | Approved | $231M | 27 |
| PCVX | Vaxcyte | Infectious Disease | 6 | Phase 3 | $10.1B | 7 |
| VERA | Vera Therapeutics | Infectious DiseaseRenal Rare | 1 | Approved | $2.15B | 6 |
| VIR | Vir Biotechnology | Infectious DiseaseOncology Rare | 2 | Phase 3 | $2.09B | 12 |
No companies match.